PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.

  title={PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.},
  author={Shin Ishihara and Yuichi Yamada and Takeshi Iwasaki and Masato Yoshimoto and Yu Toda and Kenichi Kohashi and Hidetaka Yamamoto and Yoshihiro Matsumoto and Yasuharu Nakashima and Yoshinao Oda},
  journal={Oncology reports},
The prognosis of undifferentiated pleomorphic sarcoma (UPS) is generally unfavorable. Recently, clinical trials such as SARC028 demonstrated the utility of cancer immunotherapy for soft tissue sarcomas. The aim of the present study was to assess the expression of PD‑L1 and IDO‑1 as prognostic factors and therapeutic targets. A total of 52 primary UPS cases were retrieved and two UPS cell lines were utilized for supplementary analysis. Immunohistochemical staining of anti‑PD‑L1 (28‑8), IDO‑1… 
The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma
CMTM6 expression was significantly correlated with PD-L1 expression, especially with strong PD- l1 expression inUndifferentiated pleomorphic sarcoma, and patients with UPS with a high CMTM 6 intensity score had a worse prognosis for overall survival.
Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma
The data revealed that the irlncRNA-based risk signature resulted in reliable prognosis, effectively predicted the immune landscape of patients with STS and was significantly correlated with chemosensitivity, thus providing insights into the potential role of irl NCRNAs as prognostic biomarkers and novel therapeutic targets for STS.
Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy
The role of immune cells, soluble plasmatic factors, immune checkpoints; and the expression of immune-related genes predicting survival, response to therapy, and potential immunotherapeutic agents or targets in Soft Tissue Sarcomas are summarized.
Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs
This study demonstrated that m6A-related lncRNAs were significantly associated with prognosis and tumor immune microenvironment and could function as independent prognosis-specific predictors in STS, thereby providing novel insights into the roles of m6-methylandenosine-related long non-coding RNAs in STs.
Advances in plant-derived natural products for antitumor immunotherapy.
This work intends to summarize the progress of comprehensive research on plant-derived natural products and their derivatives and discuss their possible mechanisms in regulating the immune system and their efficacy as monotherapies or in combination with regular chemotherapeutic agents.